Table 3. EGFR immunohistochemical and gene copy number status, and mTOR pathway immunohistochemical profiling.
| Gene | Total | ICC | ECC | GBC | P-value* | ||
|---|---|---|---|---|---|---|---|
| Immunohistochemistry | EGFR | 0 | 37 (32.7%) |
17 (29.8%) |
17 (42.5%) |
3 (18.8%) |
0.025 |
| 1 | 36 (31.9%) |
12 (21.0%) |
16 (40.0%) |
8 (50.0%) |
|||
| 2 | 25 (22.1%) |
15 (26.4%) |
6 (15.0%) |
4 (25.0%) |
|||
| 3 | 15 (13.3%) |
13 (22.8%) |
1 (2.5%) |
1 (6.2%) |
|||
| PTEN | 0 | 88 (77.9%) |
39 (68.4%) |
34 (85.0%) |
15 (93.8%) |
0.085 | |
| 1 | 25 (22.1%) |
18 (31.6%) |
6 (15.0%) |
1 (6.2%) |
|||
| ph-mTOR | 0 | 55 (48.7%) |
26 (45.6%) |
21 (52.5%) |
8 (50.0%) |
0.785 | |
| 1 | 58 (51.3%) |
31 (54.4%) |
19 (47.5%) |
8 (50.0%) |
|||
| ph-p70S6 | 0 | 45 (39.8%) |
29 (50.8%) |
15 (37.5%) |
1 (6.3%) |
0.015 | |
| 1 | 68 (60.2%) |
28 (49.2%) |
25 (62.5%) |
15 (93.7%) |
|||
| ph-4EBP1 | 0 | 67 (59.3%) |
34 (59.6%) |
25 (62.5%) |
8 (50.0%) |
0.785 | |
| 1 | 46 (40.7%) |
23 (40.4%) |
15 (37.5%) |
8 (50.0%) |
|||
| FISH | EGFR amplification | 6 (5.3%) |
4 (7.0%) |
0 (0.0%) |
2 (12.5%) |
0.900 | |
Note: ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma; GBC, gallbladder carcinoma.
*
Fisher's exact test corrected for multiple comparisons.